A pH-responsive polymer gel could create swallowable devices, including capsules for ultra-long drug delivery
Medical devices designed to reside in the stomach have a variety of applications, including prolonged drug delivery, electronic monitoring, and weight-loss intervention. However, these devices, often created with nondegradable elastic polymers, bear an inherent risk of intestinal obstruction as a result of accidental fracture or migration. As such, they are usually designed to remain in the stomach for a limited time.
Now, researchers at MIT’s Koch Institute for Integrative Cancer Research and Massachusetts General Hospital (MGH) have created a polymer gel that overcomes this safety concern and could allow for the development of long-acting devices that reside in the stomach, including orally delivered capsules that can release drugs over a number of days, weeks, or potentially months following a single administration.
This polymer is pH-responsive: It is stable in the acidic stomach environment but dissolves in the small intestine’s near-neutral pH, allowing for safe passage through the remainder of the gastrointestinal (GI) tract. The material is also elastic, allowing for the compression and folding of devices into easily ingestible capsules — meaning this polymer can be used to create safe devices designed for extremely prolonged residence in the stomach.
“One of the issues with any device in the GI tract is that there’s the potential for an obstruction, which is a medical emergency potentially requiring surgical intervention,” says Koch Institute research affiliate Giovanni Traverso, also a gastroenterologist at MGH and an instructor at Harvard Medical School. “A material like this represents a real advance because it is both safe and stable in the stomach environment.”
Traverso and Robert Langer, the David H. Koch Institute Professor at MIT and a member of the Koch Institute, are the senior authors of a paper in the July 27 issue of Nature Materials that describes the application of this new polymer gel for creating gastric devices. Shiyi Zhang, a postdoc at the Koch Institute, is the paper’s lead author.
Designing devices for the stomach is a complicated matter of sizes and shapes. The stomach naturally empties its contents in a matter of hours, so for devices to be retained, they must be wider than the pylorus — the valve at the end of the stomach, about 1.5 to 2 centimeters in diameter, that allows gastric contents to pass into the small intestine. However, because the most convenient path to deliver these devices is through the esophagus, which is only marginally wider than the pylorus, the researchers were interested in developing a polymer with elastic properties.
“An elastic device can be folded into something small, such as a capsule, and be easily ingested through the esophagus before expanding in the stomach, restoring its original shape,” Zhang says. “When you have a device that’s larger than the pylorus, there’s a much higher probability that it will be retained longer in the stomach.”
But the size and shape of existing devices with elastic polymers have been limited by safety concerns, as there is a greater risk for fracture if a device is too large or too complex. Because of this, the researchers wanted their polymer to also be enteric — or have a mechanism that would enable it to pass through the stomach unaltered before disintegrating in the intestines.
“To lower any possible risk of obstruction, we wanted a material that could dissolve in the intestines, thereby dissociating the device, and safely pass out of the body,” Zhang says.
To create this new material, the researchers synthesized an elastic polymer and combined it in solution with a clinically utilized enteric polymer. Adding hydrochloric acid and centrifuging the solution resulted in a flexible, yet resilient, polymer gel that exhibits both elastic and enteric properties.
The researchers used the gel polycaprolactone (PCL), a nontoxic, degradable polyester, to construct several device prototypes. They first created ring-shaped devices by using the gel to link arcs of PCL in a circular mold. These elastic devices had a diameter of 3 centimeters — wider than the pylorus — before they were folded into orally ingestible capsules.
In testing the capsules in pigs, the researchers found that the rings expanded into their original shape within 15 minutes of ingestion and remained in the stomach for up to seven days. After the device passed out of the stomach, the polymer gel dissolved, allowing for the safe passage of the small PCL pieces without obstruction. The researchers also created larger devices in various shapes that could be folded and delivered through the esophagus with the assistance of an endoscope. These devices remained in the stomach for up to five days, after which the gel similarly dissolved, allowing for the remnants of the device to safely pass.
The Latest on: Long-acting pills
via Google News
The Latest on: Long-acting pills
- Overdose reversal drugs gain support at music festivals, but not fentanyl test stripson August 3, 2022 at 6:15 am
Festival promoters are allowing lifesaving medication as fentanyl deaths surge, but volunteers are often left to distribute it, and more controversial forms of harm reduction aren't openly allowed.
- Africa: WHO Recommends Long-Acting Cabotegravir for HIV Preventionon August 3, 2022 at 12:49 am
Press Release - WHO today released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV and called for countries to consider this safe ...
- Nebraskans to benefit from $0 co-pays for insulin, emergency drugson July 29, 2022 at 3:00 pm
UnitedHealthcare, which insures more than 500,000 Nebraskans, says it will eliminate out-of-pocket costs for insulin and several other drugs for some members.
- ViiV signs agreement to allow generics of long-acting HIV PrEP in 90 countrieson July 29, 2022 at 11:30 am
Announcements made at the International AIDS Conference indicate growing momentum to expand global access to long-acting cabotegravir for HIV prevention.
- Veterinary Insulin Drugs Market Will Boost Due to Rising Awareness Regarding Animal Health and Hygieneon July 28, 2022 at 11:56 pm
Diabetes mellitus (DM), a disease experienced in larger population of animals. Diabetes among dogs, is mostly found between 4-14 years age group. Observing early symptoms of diabetes can help to ...
- WHO recommends long-acting cabotegravir for HIV preventionon July 28, 2022 at 8:36 am
According to the global health agency, CAB-LA is an intramuscular injectable, long-acting form of PrEP, with the first 2 injections administered 4 weeks apart, followed thereafter by an injection ...
- New agreement to boost access to long-acting HIV prevention drugon July 28, 2022 at 7:21 am
The licensing agreement with MPP means interested generic manufacturers can apply for sublicensing to develop, manufacture and supply generic versions of the drug for preexposure prophylaxis in 90 ...
- 5 Best Weight Loss Pills and Diet Supplements of 2022on July 25, 2022 at 2:34 pm
Burning fat and losing weight can be a real struggle, especially as we get older and our metabolism slows down more with each passing year. With ...
- List of ADHD medications: Comparing typeson July 18, 2022 at 5:00 pm
However, people can also use nonstimulant drugs, such as Strattera or Intuniv XR. Medications can have short-, medium-, or long-acting effects. The best medication for a person depends on many ...
- What’s the difference between morning-after pills and abortion medications?on July 17, 2022 at 7:02 pm
The first pill, called mifepristone ... Since the Supreme Court decision, Gray and her colleagues have seen requests for long-acting forms of contraception shoot up. “We’re seeing just ...
via Bing News